Aurora Investment Counsel purchased a new stake in Steris PLC (NYSE:STE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 31,146 shares of the medical equipment provider’s stock, valued at approximately $2,724,000. Steris accounts for about 1.4% of Aurora Investment Counsel’s holdings, making the stock its 16th largest holding.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Zions Bancorporation purchased a new position in Steris in the third quarter valued at approximately $178,000. Citigroup Inc. purchased a new position in Steris in the second quarter valued at approximately $206,000. BT Investment Management Ltd purchased a new position in Steris in the second quarter valued at approximately $210,000. GSA Capital Partners LLP purchased a new position in Steris in the third quarter valued at approximately $284,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Steris by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,276 shares of the medical equipment provider’s stock valued at $267,000 after buying an additional 311 shares during the period. Hedge funds and other institutional investors own 89.40% of the company’s stock.
In other news, insider Michael J. Tokich sold 11,000 shares of Steris stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the sale, the insider now owns 58,588 shares in the company, valued at $5,390,096. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. Company insiders own 2.55% of the company’s stock.
Steris PLC (STE) traded down $1.17 on Thursday, hitting $87.14. 498,600 shares of the stock were exchanged, compared to its average volume of 438,200. The stock has a market capitalization of $7,510.97, a price-to-earnings ratio of 51.87 and a beta of 1.27. Steris PLC has a 12 month low of $65.26 and a 12 month high of $93.39. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.80 and a quick ratio of 2.18.
Steris (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). The firm had revenue of $634.20 million for the quarter, compared to analysts’ expectations of $629.02 million. Steris had a net margin of 5.59% and a return on equity of 11.49%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.89 EPS. analysts forecast that Steris PLC will post 4.06 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd were paid a dividend of $0.31 per share. The ex-dividend date was Tuesday, November 21st. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.42%. Steris’s dividend payout ratio is currently 73.81%.
Several research analysts recently commented on the stock. KeyCorp restated an “overweight” rating and issued a $101.00 price target (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research upgraded shares of Steris from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a report on Monday, October 9th. Raymond James Financial raised their price target on shares of Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, October 16th. Finally, TD Securities lifted their price objective on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $79.50.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.